SCHEMBL5451996

SCHEMBL5451996

CCCCN1C(=O)CC(=O)N(c2ccccc2)C1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MAPT P10636 4/20 0.50
USP2 O75604 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.50
POLB P06746 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
HTT P42858 3/20 0.47
GAA P10253 3/20 0.47
HSD17B10 Q99714 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ELANE P08246 2/20 0.43
OPRK1 P41145 1/20 0.42
PDE4D Q08499 1/20 0.42
HPGD P15428 3/20 0.41
ALDH1A1 P00352 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145641 0.94 MAPT (0.55) NPC1RAB9ASMN1; SMN2MAPTUSP2
SCHEMBL17717965 0.89 MAPT (0.62) NPC1RAB9ASMN1; SMN2MAPTUSP2
SCHEMBL17717923 0.87 MEN1 (0.56) MAPTUSP2MEN1KMT2AKDM4E
SCHEMBL8348821 0.87 MAPT (0.45) NPC1RAB9ASMN1; SMN2MAPTUSP2
SCHEMBL5447443 0.87 MAPT (0.45) NPC1RAB9ASMN1; SMN2MAPTUSP2
SCHEMBL10797889 0.85 NPC1 (0.68) NPC1RAB9ASMN1; SMN2MAPTUSP2
SCHEMBL8635136 0.85 NPC1 (0.52) NPC1RAB9ASMN1; SMN2MAPTUSP2
SCHEMBL11160362 0.85 MEN1 (0.44) NPC1RAB9ASMN1; SMN2MAPTUSP2
SCHEMBL12013774 0.85 CA12 (0.48) NPC1RAB9ASMN1; SMN2MAPTUSP2
SCHEMBL11880990 0.85 MAPT (0.45) NPC1RAB9ASMN1; SMN2MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070130702-A1 Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative L'OREAL S.A. 2007-06-14 US claimed
US-4097475-A FOR POLYESTERS AND BLENDS WITH CELLULOSE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-06-27 US disclosed
US-4062836-A YELLOW CIBA-GEIGY CORPORATION (US) 1977-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070130702-A1 Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative KRT18, NDUFB5, NDUFB7 NPC1 4755/4885RAB9A 4652/4885SMN1; SMN2 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.